AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
- Enrollment initiated in Phase 3 of pivotal Phase 2/3 clinical trial for epetraborole in treatment-refractory MAC lung disease
- Presented new data at IDWeek 2023 conference showing potential for epetraborole in treating NTM lung disease and melioidosis
- Secured $150.2 million cash runway at September 30, 2023, expected to fund operations through summer 2025
- Received grant from Bill & Melinda Gates Foundation to discover novel small molecules for tuberculosis and malaria treatment
- None.
- Enrollment well underway in Phase 3 part of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease
- On track to announce Phase 2 clinical data summer 2024
-
Cash and investments of
$150.2 million
“We are incredibly proud of the significant milestones achieved recently and over the past quarter. In September, we initiated enrollment in the Phase 3 part of our pivotal Phase 2/3 clinical trial for epetraborole in treatment-refractory MAC lung disease after fully enrolling the Phase 2 part of the trial. At IDWeek in October 2023, we presented preclinical data showing the potential for epetraborole to address unmet needs for patients with Mycobacterium abscessus lung infections, for whom current treatment guidelines recommend four or more antibiotics, some of which are IV-only. There is an urgent need for more effective, novel, oral agents for this difficult-to-treat disease,” said Eric Easom, Co-Founder, President and Chief Executive Officer. “In addition to our promising progress on the epetraborole program, and consistent with our company’s mission to support global health programs, we signed key agreements during the quarter that leverage our boron-based platform for global health. Notably, in September, we received a grant from the Bill and Melinda Gates Foundation to discover novel small molecules for the treatment of tuberculosis and malaria, and in October, we announced a license agreement with the University of Georgia Research Foundation to advance the development of AN2-502998, a novel, boron-containing small molecule for Chagas disease.”
Third Quarter & Recent Business Updates:
Initiated Phase 3 Part of Pivotal Phase 2/3 Clinical Trial for Epetraborole. In September, the Company announced that it had commenced the Phase 3 part of the Phase 2/3 clinical trial after fully enrolling 80 patients in the Phase 2 part of the trial evaluating once-daily, oral epetraborole for treatment-refractory MAC lung disease. The trial is being conducted at over 100 clinical sites across the
Presented New Epetraborole Data at Infectious Disease Society of America (IDSA) IDWeek 2023 Conference. In October, three poster presentations and two oral presentations were presented at the IDWeek 2023 conference that detailed the potential of epetraborole in treating NTM lung disease and melioidosis.
Executed License from University of Georgia Research Foundation to Develop Boron-Containing Product Candidates for Chagas Disease. In October, AN2 announced that it had executed an exclusive license from the University of Georgia Research Foundation to advance the development of a boron-containing small molecule, AN2-502998 (formerly AN15368), for Chagas disease. This boron-based molecule was originally discovered by researchers at Anacor Pharmaceuticals, Inc. (a wholly owned subsidiary of Pfizer) and the University of
Received Grant from Bill & Melinda Gates Foundation. In September, AN2 announced that it received a grant from the Bill & Melinda Gates Foundation to discover novel, boron containing small molecules for the treatment of tuberculosis and malaria.
Selected Third Quarter Financial Results
- Research and Development (R&D) Expenses: R&D expenses increased for the three months ended September 30, 2023, compared to the same period during 2022 due to increased clinical trial expenses, personnel-related expenses, consulting and outside services and preclinical and research study expenses, partially offset by lower chemistry manufacturing and controls costs and other expenses.
- General and Administrative (G&A) Expenses: G&A expenses increased for the three months ended September 30, 2023, compared to the same period during 2022 due to increased personnel-related expenses and professional service fees, partially offset by a decrease in insurance costs.
-
Other Income, Net: Other income, net was
$1.5 million $0.4 million -
Net loss: Net loss was
$16.7 million $11.3 million -
Cash Position: On August 15, 2023, the Company sold an aggregate of 7,777,778 shares of the Company’s common stock at a purchase price of
$9.00 $70.0 million $150.2 million
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our initial candidate is epetraborole, which we are studying as a once-daily, oral treatment with a novel mechanism of action for patients with nontuberculous mycobacteria (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, that leads to irreversible lung damage and can be fatal. For more information, please visit our website at www.an2therapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: the timing, progress, and anticipated results from AN2's Phase 2/3 pivotal clinical trial; anticipated timing of the data readout of the Phase 2 portion of AN2’s pivotal Phase 2/3 trial; timing of enrollment in the Phase 3 portion of AN2’s pivotal Phase 2/3 trial; AN2's anticipated progress, business plans, business strategy and planned clinical trials; the potential clinical benefits and therapeutic potential of epetraborole to address unmet needs for patients with NTM lung disease and melioidosis; AN2's estimated cash runway, and planned usage and the timing of use of its capital resources; ability of AN2 to expand into other geographies; and other statements that are not historical fact. These statements are based on AN2's current estimates, expectations, plans, objectives, and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: AN2's ability to progress enrollment in its Phase 2/3 pivotal clinical trial of epetraborole; the ability of AN2 to effectively and timely make amendments to the Phase 2/3 pivotal trial design pursuant to additional FDA feedback; timely enrollment of patients in its current and future clinical trials; AN2's ability to procure sufficient supply of its product candidate for its existing and future clinical trials; the potential for results from clinical trials to differ from preclinical, early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side effects associated with AN2's product candidate; the significant uncertainty associated with AN2's product candidate ever receiving any regulatory approvals; AN2's ability to obtain, maintain or protect intellectual property rights related to its current and future product candidates; implementation of AN2's strategic plans for its business and current and future product candidates; the sufficiency of AN2's capital resources and need for additional capital to achieve its goals; global macroeconomic conditions and global conflicts; and other risks, including those described under the heading “Risk Factors” in AN2's reports to be filed with the SEC, including AN2’s Report on Form 10-Q for the quarter ended September 30, 2023. These filings, when available, are available on the investor relations section of our website at investor.an2therapeutics.com and on the SEC's website at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and AN2 undertakes no duty to update such information except as required under applicable law.
AN2 THERAPEUTICS, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share data) (unaudited) |
||||||||||||||||
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
||||||||
Research and development |
|
$ |
14,429 |
|
|
$ |
7,428 |
|
|
$ |
39,952 |
|
|
$ |
19,759 |
|
Research and development—related party |
|
|
— |
|
|
|
1,000 |
|
|
|
— |
|
|
|
1,000 |
|
General and administrative |
|
|
3,751 |
|
|
|
3,342 |
|
|
|
10,868 |
|
|
|
9,027 |
|
Total operating expenses |
|
|
18,180 |
|
|
|
11,770 |
|
|
|
50,820 |
|
|
|
29,786 |
|
Loss from operations |
|
|
(18,180 |
) |
|
|
(11,770 |
) |
|
|
(50,820 |
) |
|
|
(29,786 |
) |
Other income, net |
|
|
1,473 |
|
|
|
431 |
|
|
|
2,986 |
|
|
|
672 |
|
Net loss |
|
|
(16,707 |
) |
|
|
(11,339 |
) |
|
|
(47,834 |
) |
|
|
(29,114 |
) |
Accretion to redemption value and cumulative dividends on preferred stock |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,820 |
) |
Net loss attributable to common stockholders |
|
$ |
(16,707 |
) |
|
$ |
(11,339 |
) |
|
$ |
(47,834 |
) |
|
$ |
(30,934 |
) |
Net loss per share attributable to common stockholders, basic and diluted |
|
$ |
(0.65 |
) |
|
$ |
(0.59 |
) |
|
$ |
(2.22 |
) |
|
$ |
(2.21 |
) |
Weighted-average number of shares used in computing net loss per share, basic and diluted |
|
|
25,645,421 |
|
|
|
19,347,148 |
|
|
|
21,532,537 |
|
|
|
13,987,862 |
|
Other comprehensive loss: |
|
|
|
|
|
|
|
|
||||||||
Unrealized gain (loss) on investments |
|
|
(3 |
) |
|
|
(181 |
) |
|
|
252 |
|
|
|
(514 |
) |
Comprehensive loss |
|
$ |
(16,710 |
) |
|
$ |
(11,520 |
) |
|
$ |
(47,582 |
) |
|
$ |
(29,628 |
) |
AN2 THERAPEUTICS, INC. CONDENSED BALANCE SHEETS (in thousands) |
||||||||
|
|
September 30,
|
|
|
December 31,
|
|
||
Assets |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
32,616 |
|
|
$ |
27,219 |
|
Short-term investments |
|
|
91,202 |
|
|
|
68,840 |
|
Prepaid expenses and other current assets |
|
|
2,591 |
|
|
|
2,562 |
|
Long-term investments |
|
|
26,356 |
|
|
|
3,219 |
|
Other assets, long-term |
|
|
1,043 |
|
|
|
720 |
|
Total assets |
|
$ |
153,808 |
|
|
$ |
102,560 |
|
|
|
|
|
|
|
|
||
Liabilities and stockholders’ equity |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
4,877 |
|
|
$ |
2,122 |
|
Other current liabilities |
|
|
9,962 |
|
|
|
5,064 |
|
Other liabilities, long-term |
|
|
— |
|
|
|
2 |
|
Total liabilities |
|
|
14,839 |
|
|
|
7,188 |
|
Stockholders’ equity |
|
|
138,969 |
|
|
|
95,372 |
|
Total liabilities and stockholders’ equity |
|
$ |
153,808 |
|
|
$ |
102,560 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20231109308786/en/
Company Contacts:
Lucy O. Day
Chief Financial Officer
l.day@an2therapeutics.com
Anne Bowdidge
Investor Relations
abowdidge@an2therapeutics.com
Source: AN2 Therapeutics, Inc.
FAQ
What are the recent business updates for AN2 Therapeutics (ANTX)?
What is the purpose of the grant received from the Bill & Melinda Gates Foundation?
How much cash and investments did AN2 Therapeutics have at September 30, 2023?
What is the expected outcome of the Phase 2 clinical data announcement in summer 2024?
